FINANCIAL EXPRESS

and Other Comprehensive Income (after tax)]

Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)

Equity Share Capital

i.Basic ii.Diluted

Total Income

Profit before Tax

Date: 11.08.2022

Place: Hyderabad

Aryan Publicity Parel Village, Phone: 022-65881876 Mobile: 9320111876

Beejay Ads, Opera House

Colour Spot,

Antop Hill

Phone: 23692926 / 56051035.

Phone: 23748048 / 23714748.

Mobile: 9769238274/ 9969408835

Fulrani Advtg. & Mktg.

Phone: 24159061

Mumbai Central 9821204061

KITES Advertising, Tardeo AC Market,

Bombay Central, Phone: 66375957/8. Mobile: 9324175957

Ganesh Advertising,

I.K. Advertisers. Hornimal Circle, Phone: 22663742.

Mani's Agencies, Opp.G.P.O. Fort.

Manjyot Ads, Currey Road (E) Phone: 24700338. Mobile: 9820460262.

Phone: 2263 00232. Mobile: 9892091257.

OM Sai Ram Advtg., Currery Road Mobile: 9967375573

Pinto Advertising. Mazagaon,

Mumbai Central Mobile: 9819891116

Sarjan Advertising,

Phone: 66626983

S. Arts Advtg. Masjid

Girgaon,

Prabhadevi.

Dadar(W),Phone: 2422 9241/ 2422 0445.

Mahim (W),

Mahim (W). Phone: 24221461

Jay Publicity. Dadar(E),

Pallavi Advtg.

Dadar (W),

Dadar (W), Phone: 24440631

Stylus Arts,

Dadar (W), Phone: 24304897

Time Advertising,

Matunga (W), Phone: 2446 6191

Vijaya Agencies, Dadar (W),

Bandra (E) Phone: 26552207

Kirti Agencies,

Phone: 26047542.

Santacruz (W), Mobile: 9869463650

Vile Parle (E),

Phone: 2617 6310

Carl Advertising,

Keyon Publicity Andheri (E.)

Phone: 28253077 Mobile: 9920992393

Andheri (W).

Mobile: 9820069565

Phone: 6696 3441 / 42.

AD Support Advertising,

Gauri Press Communication.

Khar (W).

Phone: 2422 5672.

Mobile: 9920640689

Space Age Advertising,

Mobile: 9869666222

Phone: 24124640

Mobile: 9869109765

Mobile: 9869131962

Shree Swami Samarth Advertising,

Phone: 23415111

Sanjeet Communication

Phone: 40024682/40792205.

Yugarambha Advertising,

Phone: 2386 8065. Mobile: 9869074144. Ambition Advertising,

Phone: 24210792 / 94. B. Y. Padhye Publicity,

DATEY Advertising, Datev Bhavan, Dadar (W) Mobole: 8452846979/9930949817

Central Advertising Agency,

Charudatta Advertising,

Phone: 24468656 / 24465555

Tardeo.

Phone: 23701070. Mobile: 9869040181.

Abdul Rehman Street,

Phone: 2342 9163 / 2341 4596.

CLASSIFIED CENTRES IN MUMBAI

Profit for the Period

SI.

No.

VIVO BIO TECH LIMITED CIN: L65993TG1987PLC007163 Registered Office: Survey # 349/4, Pregnapur Village, Gajwel, Siddipet District, Hyderabad, Telangana - 502311 Email: investors@vivobio.com; Website: www.vivobio.com EXTRACT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS OF VIVO BIO TECH LIMITED FOR THE QUARTER ENDED 30* JUNE, 2022 QUARTER ENDED YEAR ENDED Particulars 30.06.2022 31.03.2022 31.03.2022 30.06.2021 **Un-Audited** Refer Note#2 Un-Audited Audited Total Income from Operations 1,126.42 1,515.28 1,321.78 5,148.93 Net Profit / (Loss) for the period (before Tax, 68.63 -162.52 219.06 447.23 Exceptional and/or Extraordinary items#) Net Profit / (Loss) for the period before tax (after 68.63 -162.52 219.06 447.23 Exceptional and/or Extraordinary items#) Net Profit / (Loss) for the period after tax (after 31.60 123.94 Exceptional and/or Extraordinary items#) -68.71 220.16 Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax)

31.60

0.22

0.22

1,487.65

-68.71

-0.49

-0.49

(Refer Note#2)

1,515.28

(161.74)

(67.92)

1,426.35

123.94

1,420.45

0.87

0.84

(Un-Audited)

1.321.16

218.44

123.32

220.16

1.56

1.56

1,426.35

1. The above Un-Audited Financial Results as reviewed and recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 10th August, 2022.

2. The figures for the guarter ended 31st March 2022 are the balancing figure between the audited figures of the full financial year and the published year-to-date figures upto the 3rd quarter of respective financial years which were subject to Limited review by the Statutory Auditor of the Company. The Consolidated Results include results of all subsidiaries.

The above is an Extract of the detailed format of Un-Audited Financial Results filed with stock exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the quarter ended 30th

June, 2022 are available on the stock exchange website www.bseindia.com and Company's website www.vivobio.com Summarized Standalone Financial Information (Un-Audited) (Rs. In Lacs) QUARTER ENDED YEAR ENDED Particulars 31.03.2022 30.06.2022 30.06.2021 31.03.2022 (Un-Audited)

1,126.42

68.63

31.61

220.33 For Vivo Bio Tech Limited Sd/-

(Audited)

5.148.31

447.39

M. Kalyan Ram Whole Time Director DIN: 02012580

VIPUL ORGANICS LIMITED

(CIN: L24110MH1972PLC015857) Registered Office: 102, Andheri Industrial Estate, Off. Veera Desai Road, Andheri (West), Mumbai - 400053 Corporate Office: B 603-A, Kaledonia, Sahar Road, Off. W.E. Highway, Andheri (East), Mumbai - 400069 Telephone no. 022-66139999, Fax no. 022- 66139977/75 Email Id: info@vipulorganics.com Website: www.vipulorganics.com **Extract of Un-audited Standalone and Consolidated Financial Results for**

the guarter ended 30th June, 2022

Sr.	Particulars		Standalone	•	Consolidated			
No.		Qua	rter ended	Year ended	Quar	Year ended		
	1					30.06.2021		
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)	
1	Total income from operations (net)	3,793.21	3,330.82	13,515.98	3,793.21	3,330.81	13515.98	
2	Net Profit /(loss) for the period (before tax,							
	Exceptional and /or Extra ordinary items)	153.15	205.98	975.86	152.85	205.66	974.13	
3	Net Profit /(loss) for the period before tax							
	(after Exceptional and /or Extra ordinary items)	153.15	205.98	975.86	152.85	205.66	974.13	
4	Net Profit /(loss) for the period after tax							
	(after Exceptional and /or Extra ordinary items)	106.08	156.68	698.56	105.78	156.34	696.8	
5	Total Comprehensive Income for the period							
	[(comprising profit / (loss) for the period (after tax)							
	and other comprehensive income (after tax)]	105.05	156.89	691.66	104.75	156.56	689.9	
6	Paid up Equity Share Capital							
	(Face value of Rs. 10/- each)	1281.19	954.95	1024.95	1,281.19	954.95	1,024.9	
7	Reserves (excluding Revaluation Reserves as							
	per Balance Sheet of previous accounting year)	0	0	4229.62	0	0	4206.8	
8	Earning per Equity share of Rs. 10/- each							
	(a) Basic	0.82	1.38	5.71	0.82	1.38	5.7	
	(b) Diluted	0.82	1.38	5.71	0.82	1.38	5.7	

Place: Mumbai

Date: 11th August, 2022

 The above Un-audited Financial Results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 11th August, 2022 and the Statutory Auditors of the Company have carried out 'Limited Review' of the same.

The above is an extract of the detailed format of the Un-audited Financial Results for the quarter ended 30th June, 2022 filed with the BSE Limited, where the shares of the Company are listed, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.vipulorganics.com).

3. Previous periods figures have been rearranged/regrouped wherever considered necessary to confirm to the presentation of the current period. All figures of financial results have been rounded off to nearest lakh rupees, except EPS.

For VIPUL ORGANICS LIMITED

Sd/-Vipul P. Shah

(Rs. in Lakh except EPS)

Managing Director DIN: 00181636

Place : Kolkata

Date: 11.08.2022

THIRANI PROJECTS LIMITED CIN: L45209WB1983PLC036538

Regd. Office: Subol Dutt Building, 13, Brabourne Road, Kolkata-700 001 Telephone: 033 2242 1536, E-mail: info@thiraniprojects.com, Wetsite: www.thiraniprojects.com

Statement of Unaudited Standalone Financial Results for the Quarter ended June 30, 2022 (Rs. in Lakhs

ended

ended

ended

ended

PARTICULARS	June 30, 2022	March 31, 2022	June 30, 2020	March 31, 2022
į į	(Un-Audited)	(Audited)	(Unaudited)	(Audited)
Total income from operations (net) Net Profit / (Loss) from ordinary	24.117	13.380	23.342	83.551
activities after tax	17.483	-38.341	20.412	14.211
Net Profit / (Loss) for the period after tax (after Extraordinary items)	17.483	-38.341	20.412	14.211
Equity Share Capital Reserves (excluding Revaluation	2021.288	2021.288	2021.288	2021.288
Reserve as shown in the Balance Sheet of Previous year) Earnings Per Share (before extraordinary items) (of Rs. 10/- each)	0.000	0.000	0.000	-142.172
Basic :	0.086	-0.190	0.121	0.070
Diluted :	0.086	-0.190	0.121	0.070
Earnings Per Share (after extraordinary items) (of Rs. 10/- each)				
Basic :	0.086	-0.190	0.121	0.070
Diluted :	0.086	-0.190	0.121	0.070
Note:				

(Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter ended 30.06.2022 is available on the Stock Exchange websites.

Company's website: http://www.thiraniprojects.com/financial-result.php BSE Limited: www.bseindia.com

Notes: 1) The said financial results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meetings held

The above is an extract of the detailed format of Financial Results for the Quarter

ended 30.06.2022 filed with the Stock Exchange under Regulation 33 of the SEBI

on 11th August 2022. 2) In accordance with the requirements under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Statutory Auditors have performed a limited review of the financial results of Thirani Projects Limited for the quarter ended 30th June 2022. There are no qualifications in the

limited review report issued for the said period. For and on behalf of the Board of Thirani Projects Limited

Utpal Dey Managing Director DIN: 06931935

glenmark

GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026. Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099. Tel No.: +91-22-4018 9999 Fax No.: +91-22-4018 9986

Email: complianceofficer@glenmarkpharma.com **Website:** www.glenmarkpharma.com CIN: L24299MH1977PLC019982

Standalone

Statement of unaudited financial results for the quarter ended 30 June, 2022

(₹ In Millions)

			Standalone				Consolidated			
	Particulars	Quarter ended 30/06/2022 (Unaudited)	Quarter ended 31/03/2022 (Audited)	Quarter ended 30/06/2021 (Unaudited)	Year ended 31/03/2022 (Audited)	Quarter ended 30/06/2022 (Unaudited)	Quarter ended 31/03/2022 (Audited)	Quarter ended 30/06/2021 (Unaudited)	Year ended 31/03/2022 (Audited)	
	Revenue from operations									
	(a) Net sales	18,722.38	17,208.87	21,292.40	80,173.80	27,200.97	29,611.52	29,461.48	121,741.98	
	(b) Other operating income	396.92	646.57	128.77	1,242.01	571.92	579.95	187.47	1,307.05	
	Total revenue from operations	19,119.30	17,855.44	21,421.17	81,415.81	27,772.89	30,191.47	29,648.95	123,049.03	
l II	Other income	3,465.18	1,789.82	1,382.08	6,146.28	1,831.55	1,072.02	586.49	1,666.74	
III	Total income (I + II)	22,584.48	19,645.26	22,803.25	87,562.09	29,604.44	31,263.49	30,235.44	124,715.77	
IV	Expenses									
	(a) Cost of materials consumed	7,168.42	6,899.75	8,459.53	29,930.36	8,708.04	7,899.34	9,172.19	32,787.57	
	(b) Purchases of stock-in-trade	940.54	978.10	1,401.60	4,816.20	2,518.47	2,384.01	3,185.91	11,176.65	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(300.82)	(208.04)	41.27	(161.32)	(1,106.05)	25.34	(968.41)	(111.37)	
	(d) Employee benefits expense	3,022.97	2,855.24	2,641.22	11,931.96	6,363.67	5,776.78	5,964.19	24,474.18	
	(e) Finance costs	397.63	740.10	590.15	2,360.41	599.89	868.54	756.04	2,980.99	
	(f) Depreciation, amortisation and impairment expense	450.33	417.72	374.42	1,596.95	1,467.55	1,315.23	1,130.72	4,867.15	
	(g) Other expenses	3,949.95	5,714.54	3,311.07	18,016.40	6,972.75	9,471.99	6,559.28	31,519.01	
	Total expenses (IV)	15,629.02	17,397.41	16,819.26	68,490.96	25,524.32	27,741.23	25,799.92	107,694.18	
V	Profit/(loss) before exceptional items and tax (III - IV)	6,955.46	2,247.85	5,983.99	19,071.13	4,080.12	3,522.26	4,435.52	17,021.59	
VI	Exceptional items loss/(gain) (Refer note 5)	-	_	_	(4,303.33)	-	825.33	-	2,609.13	
VII	Profit/(loss) before tax (V - VI)	6,955.46	2,247.85	5,983.99	23,374.46	4,080.12	2,696.93	4,435.52	14,412.46	
VIII	Tax expense :						.			
	Current tax	1,103.57	402.65	1,050.89	4,110.78	1,352.37	1,157.19	1,445.99	5,466.49	
	Deferred tax	926.08	(210.77)	38.95	(714.21)	616.68	(185.94)	(75.74)	(990.52)	
IX	Profit/(loss) for the period (VII - VIII)	4,925.81	2,055.97	4,894.15	19,977.89	2,111.07	1,725.68	3,065.27	9,936.49	
	Profit/(loss) for the period attributable to:						.			
	- Non-controlling interests									
	- Owners of the Company	-		_	.	185.77	169.81	(0.37)	519.38	
X	Other comprehensive income	4,925.81	2,055.97	4,894.15	19,977.89	1,925.30	1,555.87	3,065.64	9,417.11	
	A (i) Items that will not be reclassified to profit or loss	91.37	14.77	25.65	30.53	99.78	339.51	25.59	315.02	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(11.06)	(8.98)	(8.96)	(14.48)	(11.16)	(50.18)	(8.52)	(48.53)	
	B (i) Items that will be reclassified to profit or loss	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	` -	` [` []	1,915.98	(25.16)	975.95	500.62	
	(ii) Income tax relating to items that will be reclassified to profit or loss	_		_	_	(220.32)	72.76	(67.32)		
XI	Total comprehensive income for the period/ year	5,006.12	2,061.76	4,910.84	19,993.94	3,895.35	2,062.61	3,990.97	10,703.60	
XII	Total comprehensive income attributable to:		_,	,,==:::		,,,,,,,,	_,,	5,223.5		
	- Non-controlling interests	_		_	_	185.89	170.24	(0.37)	519.97	
	- Owners of the Company	5,006.12	2,061.76	4,910.84	19,993.94	3,709.46	1,892.37	3,991.34	10,183.63	
XIII	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	
	Other equity		202.17	202.17	167,103.70	202.17	202.17	202.17	90,584.30	
XV	Earning per share (EPS)				107,100.70				20,00 1.00	
'`'	(of Re 1/- each) (not annualised)*									
	Basic EPS (in Rupees)	17.46	7.29	17.34	70.80	6.82	5.51	10.86	33.37	
	Diluted EPS (in Rupees)	17.46		17.34	70.80	6.82	5.51	10.86	33.37	

st except for the year ended 31 March

The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The above results were reviewed by the Audit Committee at its meetings held on 9th August, 2022 and approved by the Board of Directors at its meeting held on 10th August, 2022. The results for the quarter ended 30th June, 2022 presented were subjected to a "Limited"

Review" by the statutory auditors of the Company who have issued an unmodified review report on the said results. The figures for the quarter ended 31st March 2022 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended 31st December, 2021.

The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are

notified. Exceptional item:

Consolidated result:

Exceptional item of Rs. 825.33 for the previous quarter ended 31 March, 2022 comprise of recall of products and related remediation cost of Monroe manufacturing site (USA) and Rs. 2,609.13 for the year ended 31 March, 2022 comprises of impairment of certain intangible assets and recall of products and related remediation cost of Monroe manufacturing site (USA). Standalone result:

On 3rd August, 2021, Glenmark Life Sciences Limited (GLS) completed allottment of shares as part of its Initial Public Offering (IPO) and Offer for Sale (OFS). The company offered 6.3 million equity shares of Rs 2 each through OFS and resulted in a gain of Rs 4.303.33 (net

of related expenses and cost of equity shares) and recorded as an exceptional item in the standalone financial results. Pursuant to requirements of Ind AS 110 para 23 and B96 such gain and tax thereon is directly recognised in equity in consolidated financial statements Post the sale and IPO, the Company's holding in equity shares of GLS has reduced from 100% to 82.84 %. The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one

reportable segment, i.e., Pharmaceuticals.

As at 30th June, 2022, pursuant to Employee Stock Options Scheme 2016, 78,717 options were outstanding, which upon exercise are convertible into equivalent number of equity shares. 8 The list of subsidiaries as of 30th June, 2022 is provided in Annexure A.

The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter ended 30th June, 2022. 10 Diluted EPS has been computed considering the effect of conversion of ESOPs.

11 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Annexure A

List of entities included in the consolidated financial results for quater ended 30 June 2022

1 Glenmark Pharmaceuticals Europe Ltd., U.K. 2 Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. (liquidated with effect from 4 January 2022) 3 Glenmark Pharmaceuticals S.R.O. 4 Glenmark Pharmaceuticals SK, S.R.O. 5 Ichnos Sciences SA 6 Glenmark Holding S.A. 7 Glenmark Pharmaceuticals SP z.o.o. 8 Glenmark Pharmaceuticals Inc. 9 Glenmark Pharmaceuticals Inc. 10 G Pharmaceuticals Colombia SAS, Inc. 22 Glenmark Pharmaceuticals (Nigeria) Ltd 23 Glenmark Pharmaceuticals (Australia) Pty Ltd 25 Glenmark Pharmaceuticals (Oligeria) Ltd 27 Glenmark Pharmaceuticals (Nigeria) Ltd 27 Glenmark Pharmaceuticals (Thailand) Co. Ltd 28 Glenmark Pharmaceuticals B.V. 29 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Kenya Ltd 32 Viso Farmaceutica S.L., Spain 33 Glenmark Specialty SA 34 Glenmark Pharmaceuticals Distribution s.r.o. 35 Glenmark Pharmaceuticals Nordic AB 36 Glenmark Ukraine LLC 37 Glenmark-Pharmaceuticals Ecuador S.A. 38 Glenmark Pharmaceuticals Singapore Pte. Ltd. 39 Ichnos Sciences Biotherapeutics SA 40 Ichnos Sciences Inc., USA 41 Glenmark Life Sciences Limited

For and on behalf of the Board of Directors

Glenn Saldanha **Chairman & Managing Director**

Mumbai, 10 August, 2022

9

Lokhandwala Advertising, Phone: 26364274 / 26316960.

financialexp.

सळई उद्योगांवर छापे

५६ कोटींची रोकड, १४ कोटींचे सोने जप्त; प्राप्तिकर विभागाची कारवाई

लोकसत्ता विशेष प्रतिनिधी

औरंगाबाद, जालना : राज्यातील जालना, औरंगाबाद, नाशिक आणि मंबईमध्ये सळई उद्योगाशी संबंधित ठिकाणांवर प्राप्तिकर विभागाने छापे त्यात १२० कोटींची करचुकवेगिरी उघड झाली असून, ५६ कोटींची रोकड, १४ कोटींचे सोने जप्त करण्यात आले.

१ ते ८ ऑगस्टदरम्यान प्राप्तिकर विभागाचे २०० पेक्षा अधिक अधिकारी आणि कर्मचारी जालना शहरात ठाण मांड्न होते. नाशिकमधील पाच पथकांनी ही कारवाई केली. जालना औद्योगिक वसाहतीमधील एसआरजे पित्ती स्टील्स प्रा. लि. आणि कालिका स्टील्स अलॉय प्रा. लि. या दोन उद्योगांची नावे प्राप्तिकर छाप्याबाबत गेल्या आठवडाभरापासून चर्चेत आहेत. याशिवाय विमलराज सिंघवी तसेच प्रदीप बोरा या दोन व्यावसायिकांची नावेही प्राप्तिकर विभागाच्या छाप्यांच्या अनुषंगाने चर्चेत आहेत. गुरुवारी या छाप्यांतील बेहिशेबी मालमत्तेचे वृत्त आणि छाप्यांच्या वेळी सापडलेल्या कोट्यवधी रुपयांच्या नोटांची छायाचित्रे प्रसारमाध्यमांतुन समोर आली. त्यामुळे प्राप्तिकर कार्यालयाच्या नाशिक येथील अन्वेषण आणि शोध विभागाने

फसवणुक

करणाऱ्या

महिलेला अटक

ठाणे : आभासी चलनात गुंतवणूक

केल्यास मासिक १५ ते ५०

टक्क्यांपर्यंत परतावा मिळेल असे

सांगून गुंतवणूकदारांची फसवणूक

करणाऱ्या बबिता कुमार (३१) हिला ठाणे पोलिसांच्या सायबर गुन्हे

अन्वेषण शाखेने दिल्ली येथून

अटक केली आहे. बबिता हिचा बँक तपशील पोलिसांनी तपासला

असता त्यामध्ये अडीच कोटी रुपयांची उलाढाल झाल्याचे आढळून आले आहे. त्यामुळे देशभरातील हजारो नागरिकांची फसवणूक झाल्याचा अंदाज पोलिसांकडून व्यक्त केला जात आहे. फसवणूक झालेले तक्रारदार हे कल्याण भागात राहतात. काही महिन्यांपूर्वी त्यांना टेलेग्राम या समाजमाध्यमावर मायवॉलेट ट्रेडिंग प्रायव्हटे लिमिटेड नावाची एक कंपनी आढळून आली होती. या कंपनीच्या माध्यमातून आभासी चलनात गुंतवणूक केल्यास मासिक १५ ते ५० टक्क्यांचा परतावा मिळेल असे सांगितले जात होते. त्यामुळे तक्रारदारासह तीन जणांनी साडेसात लाख रुपये गुंतविले होते. महिने उलटूनही त्यांना परतावा मिळत नव्हता. आपली फसवणुक झाल्याचे लक्षात आल्यानंतर त्यांनी याप्रकरणी खडकपाडा पोलीस ठाण्यात तक्रार दाखल केली होती.

शिवपुतळ्यासाठी

(पान ३ वरून) आले नसल्याचे कळते. शिवरायांचा पुतळा उभारणीबाबत रेल्वे बोर्ड आणि मध्य रेल्वेकडे वारंवार मागणी करण्यात आली. परंतु त्याकडे दुर्लक्ष केल्याचा आरोप, शिवसेना खासदार अरविंद सावंत यांनी केला आहे. हा

पतळा सीएसएमटीच्या दर्शनी भागात

(मंबई महानगरपालिका समोर)

उभारण्याची पुन्हा एकदा मागणी

सशोभीकरणाचे काम हे मध्य रेल्वे

अभियंता विभागाच्या अखत्यारीत

येते. मात्र या विभागाला महाराजांचा पतळा उभा करण्याबाबत रेल्वे बोर्ड

आणि मध्य रेल्वे महाव्यवस्थापक

कार्यालयाकडून कोणत्याही सूचना

देण्यात आलेल्या नाहीत, असे एका

वरिष्ठ अधिकाऱ्याने सांगितले.

त्यामुळे हा पुतळा बंद गोदामातच

केल्यानंतर त्यावर धातूचा

ठेवण्यात येणार आहे.

र्विर्धि फायबरचे काम पूर्ण

लागले असते, त्यापूर्वी काम

दिली. मात्र, काम

जे.जे.स्कूल ऑफ आर्ट्स

मुलामा चढवण्याचा अंतिम टप्पा

होता. त्यासाठी सात ते आठ महिने

थांबविण्याची सूचना मध्य रेल्वेने

थांबविण्यामागील नेमके कारण

– प्रा. विश्वनाथ साबळे, अधिष्ठाता,

मात्र त्यांनी स्पष्ट केले नाही.

परिसराच्या

करणार असल्याचे ते म्हणाले.

... पुतळा अडगळीतच

सीएसएमटी

लोकप्रतिनिधी

सरसावले



कर्मचाऱ्यांच्या नावे लॉकर

जालन्यातील स्टील उद्योगांनी कोलकाता येथे बनावट कंपन्या तयार करून गैरव्यवहार केल्याचे या छाप्यात स्पष्ट झाले. काही कंपन्यांनी कर्मचाऱ्यांच्या नावे नागरी सहकारी बँकांमध्ये लॉकर उघडले अधिकचा खर्च दाखवून वेगवेगळ्या प्रकराची अनुदाने मिळवून गैरव्यवहार करण्यात आल्याचे स्पष्ट झाले आहे. विविध ठिकाणी केलेल्या लॉकरच्या तपासणीत बेहिशेबी संपत्ती आढळन आल्याचा दावा प्राप्तिकर विभागाकडून करण्यात आला.

जालन्यात कारवाई कुठे? एसआरजे पित्ती स्टील्स प्रा. लि., कालिका स्टील्स् अलॉय प्रा. लि या कंपन्यांवर कारवाई झाल्याचे समजते. तसेच विमलराज सिंघवी आणि प्रदीप बोरा या व्यावसायिकांवर कारवाई झाल्याची चर्चा आहे

केलेल्या कारवाईची व्यापकता स्पष्ट झाली. जालना शहरात १२ मोठ्या व २० च्या आसपास सळई उत्पादक कंपन्या आहेत. मध्य प्रदेश, कर्नाटक, गुजरात, आंध्र प्रदेशात सळयांचा पुरवठा या उद्योगातून केला जातो. गेल्या काही दिवसांपूर्वी वस्तू सेवा कर चोरी करणाऱ्या व्यापारी व उद्योगाच्या साठ्याची तपासणी करण्यासाठी राज्यातील वस्तू सेवा कर विभागानेही कारवाई केली होती. १५०

कोटींपेक्षा अधिक वीज देयके भरणाऱ्या जालना उद्योग समूहातील कर चुकवेगिरीची चर्चा नेहमी होत असे. मात्र, झालेल्या कारवाईची माहिती उपलब्ध होत नव्हती. जिल्हाधिकारी तुकाराम मुंडे यांनी प्रदुषण करणाऱ्या सळया उत्पादक कारखान्यांना नोटिस दिल्या होत्या. या वेळी प्राप्तिकर विभागाच्या प्रसिद्धिपत्रकात कर चुकवेगिरीच्या कार्यपद्धतीचाही उल्लेख करण्यात आला आहे.



शिळफाटा, डोंबिवलीत वाहतूक संथगतीने

लोकसत्ता प्रतिनिधी

खङ्ट्यांच्या कल्याण अडथळ्यांमुळे कल्याण-शिळफाटा रस्ता, डोंबिवली, कल्याणमधील अंतर्गत रस्त्यांवर वारंवार वाहतुक कोंडी होते. रक्षाबंधनामुळे गुरुवारी रस्त्यांवर वाहनांची वर्दळ वाढल्याने ही समस्या आणखी बिकट झाली.

वाहतूक शिळफाटा रस्त्यावर मानपाडा ते

पलावा चौकापर्यंत जाण्यासाठी एक तास लागत होता. कल्याणकडून पत्रीपूल मार्गे अनेक वाहने डोंबिवलीत ठाकुर्लीतून येत होती. ठाकुर्ली हनुमान मंदिराजवळील अरुंद रस्ता, खड्डे, त्यात डोंबिवलीत पेंडसेनगर, पश्चिमेकडून कल्याणकडे जाणारी वाहने एकाच वेळी अरुंद रस्त्यावर

ठाकुर्लीतील रस्त्यावर कोंडी

वाहनचालकांनी घरडा डोंबिवलीत सर्कलमार्गे जाण्याचा प्रयत्न केला. घरडा सर्कल ते टिळक पुतळापर्यंत कोंडी होती.

गोग्रासवाडी, संत नामदेव पथावरून येणारी वाहनेही येथे आल्याने वाहन कोंडीत भर पडली. शिळफाटा दिशेने कल्याणकडे येण्यासाठी एक ते सव्वा तासाचा वेळ लागत

शालेय पोषण आहारासाठी आधार कार्ड सक्तीचे

लोकसत्ता प्रतिनिधी

पुणे: राज्यातील शासकीय आणि अनुदानित शाळांमध्ये आधार कार्ड असलेल्या विद्यार्थ्यांनाच आता शालेय पोषण आहाराचा लाभ दिला जाणार आहे. त्यामुळे येत्या डिसेंबरपर्यंत विद्यार्थ्यांचे आधार कार्ड काढून ते शालेय पोषण आहाराशी जोडण्याचे निर्देश शिक्षण विभागाकडून देण्यात आले असून, अद्याप आधार कार्ड नसलेल्या विद्यार्थ्यांचे आधार कार्ड काढण्याचे काम शिक्षकांना करावे लागत आहे.

वित्त विभागाच्या शासन निर्णयानुसार वैयक्तिक लाभाच्या योजना पात्र लाभार्थ्यांपर्यंत पोहोचवण्यासाठी लाभार्थ्यांचा माहितीसाठा (डेटाबेस) तयार करून तो आधार कार्डशी जोडला जाणार आहे. त्यानुसार त्यानुसार शालेय पोषण आहार योजनेचा लाभ घेणाऱ्या विद्यार्थ्यांची आधार कार्ड नोंदणी प्रक्रिया डिसेंबर २०२२ पर्यंत पूर्ण करणे अनिवार्य आहे. पात्र सर्व शाळांतील लाभार्थ्यांची आधार कार्ड नोंदणी पुर्ण झालेली असणे आवश्यक आहे. मात्र अद्यापही काही लाभार्थ्यांची आधार नोंदणी पूर्ण

विद्यार्थ्यांचे आधार कार्ड काढण्यासाठी शिक्षक काम करत आहेत. मात्र कागदपत्रे अपूर्ण असणे, विद्यार्थ्यांच्या बोटांचे ठसे न उमटणे आदी तांत्रिक अडचणी येत आहेत. प्राथमिक शिक्षण संचालनालयाच्या पत्रानुसार डिसेंबरअखेरीपर्यंत आधार जोडणी प्रक्रिया पूर्ण करणे आवश्यक आहे. आधार जोडणी नसलेल्या विद्यार्थ्यांना जानेवारीपासून शालेय पोषण आहारापासून वंचित ठेवले जाणार का, असा प्रश्न उपस्थित होत आहे. - महेंद्र गणपुले, राज्य प्रवक्ते, मुख्याध्यापक महामंडळ

झालेली नाही. त्यामुळे संबंधित लाभार्थ्यांची आधार नोंदणी करून घेण्यासाठी कालबद्ध कार्यक्रमाचे नियोजन करावे. त्याचप्रमाणे दर महिन्याच्या २८ तारखेपर्यंत या विद्यार्थ्यांची माहिती सादर करण्याच्या सूचना प्राथमिक शिक्षण संचालनालयाकडून शिक्षणाधिकाऱ्यांना देण्यात आल्या आहेत. त्यामुळे १ जानेवारी २०२३ पासून आधार कार्डची जोडणी शालेय पोषण आहाराशी असलेल्या विद्यार्थ्यांनाच शालेय पोषण आहाराचा लाभ देण्यात येणार असल्याचे स्पष्ट झाले आहे.

glenmark

GLENMARK PHARMACEUTICALS LIMITED

समोरासमोर

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026. Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099. Tel No.: +91-22-4018 9999 Fax No.: +91-22-4018 9986

Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter ended 30 June, 2022

Standalone

(₹ In Millions)

Consolidated

			Standalone				Consolidated			
	Particulars	Quarter ended 30/06/2022 (Unaudited)	Quarter ended 31/03/2022 (Audited)	Quarter ended 30/06/2021 (Unaudited)	Year ended 31/03/2022 (Audited)	Quarter ended 30/06/2022 (Unaudited)	Quarter ended 31/03/2022 (Audited)	Quarter ended 30/06/2021 (Unaudited)	Year ended 31/03/2022 (Audited)	
ı	Revenue from operations									
	(a) Net sales	18,722.38	17,208.87	21,292.40	80,173.80	27,200.97	29,611.52	29,461.48	121,741.98	
	(b) Other operating income	396.92	646.57	128.77	1,242.01	571.92	579.95	187.47	1,307.0	
	Total revenue from operations	19,119.30	17,855.44	21,421.17	81,415.81	27,772.89	30,191.47	29,648.95	123,049.03	
Ш	Other income	3,465.18	1,789.82	1,382.08	6,146.28	1,831.55	1,072.02	586.49	1,666.74	
Ш	Total income (I + II)	22,584.48	19,645.26	22,803.25	87,562.09	29,604.44	31,263.49	30,235.44	124,715.77	
IV	Expenses									
	(a) Cost of materials consumed	7,168.42	6,899.75	8,459.53	29,930.36	8,708.04	7,899.34	9,172.19	32,787.57	
	(b) Purchases of stock-in-trade	940.54	978.10	1,401.60	4,816.20	2,518.47	2,384.01	3,185.91	11,176.65	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(300.82)	(208.04)	41.27	(161.32)	(1,106.05)	25.34	(968.41)	(111.37)	
	(d) Employee benefits expense	3,022.97	2,855.24	2,641.22	11,931.96	6,363.67	5,776.78	5,964.19	24,474.18	
	(e) Finance costs	397.63	740.10	590.15	2,360.41	599.89	868.54	756.04	2,980.99	
	(f) Depreciation, amortisation and impairment expense	450.33	417.72	374.42	1,596.95	1,467.55	1,315.23	1,130.72	4,867.15	
	(g) Other expenses	3,949.95	5,714.54	3,311.07	18,016.40	6,972.75	9,471.99	6,559.28	31,519.01	
	Total expenses (IV)	15,629.02	17,397.41	16,819.26	68,490.96	25,524.32	27,741.23	25,799.92	107,694.18	
V	Profit/(loss) before exceptional items and tax (III - IV)	6,955.46	2,247.85	5,983.99	19,071.13	4,080.12	3,522.26	4,435.52	17,021.59	
VI	Exceptional items loss/(gain) (Refer note 5)	-	-	-	(4,303.33)	-	825.33	-	2,609.13	
VII	Profit/(loss) before tax (V - VI)	6,955.46	2,247.85	5,983.99	23,374.46	4,080.12	2,696.93	4,435.52	14,412.46	
VIII	Tax expense :									
	Current tax	1,103.57	402.65	1,050.89	4,110.78	1,352.37	1,157.19	1,445.99	5,466.49	
	Deferred tax	926.08	(210.77)	38.95	(714.21)	616.68	(185.94)	(75.74)	(990.52)	
IX	Profit/(loss) for the period (VII - VIII)	4,925.81	2,055.97	4,894.15	19,977.89	2,111.07	1,725.68	3,065.27	9,936.49	
	Profit/(loss) for the period attributable to:									
	- Non-controlling interests									
	- Owners of the Company	_	-	-	-	185.77	169.81	(0.37)	519.38	
Х	Other comprehensive income	4,925.81	2,055.97	4,894.15	19,977.89	1,925.30	1,555.87	3,065.64	9,417.11	
	A (i) Items that will not be reclassified to profit or loss	91.37	14.77	25.65	30.53	99.78	339.51	25.59	315.02	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(11.06)	(8.98)	(8.96)	(14.48)	(11.16)	(50.18)	(8.52)	(48.53)	
	B (i) Items that will be reclassified to profit or loss		_	-	-	1,915.98	(25.16)	975.95	500.62	
	(ii) Income tax relating to items that will be reclassified to profit or loss	_	_	-	-	(220.32)	72.76	(67.32)		
ΧI	Total comprehensive income for the period/ year	5,006.12	2,061.76	4,910.84	19,993.94	3,895.35	2,062.61	3,990.97	10,703.60	
XII	Total comprehensive income attributable to:	,	,	,	·	·	,	,	ŕ	
	- Non-controlling interests	_	_	-	_	185.89	170.24	(0.37)	519.97	
	- Owners of the Company	5,006.12	2,061.76	4,910.84	19,993.94	3,709.46	1,892.37	3,991.34	10,183.63	
XIII	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	
	Other equity				167,103.70				90,584.30	
XV	Earning per share (EPS)								/	
	(of Re 1/- each) (not annualised)*									
	Basic EPS (in Rupees)	17.46	7.29	17.34	70.80	6.82	5.51	10.86	33.3	
	Diluted EPS (in Rupees)	17.46	7.29	17.34	70.80	6.82	5.51	10.86	33.37	

- 1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The above results were reviewed by the Audit Committee at its meetings held on 9th August, 2022 and approved by the Board of Directors at its meeting held on 10th August, 2022. The results for the quarter ended 30th June, 2022 presented were subjected to a "Limited" Review" by the statutory auditors of the Company who have issued an unmodified review report on the said results.
- The figures for the quarter ended 31st March 2022 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended 31st December, 2021.
- The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are
- Exceptional item:
- 5 Consolidated result

Mumbai, 10 August, 2022

Exceptional item of Rs. 825.33 for the previous quarter ended 31 March, 2022 comprises of impairment of certain intangible assets and recall of products and related remediation cost of Monroe manufacturing site (USA)

On 3rd August, 2021, Glenmark Life Sciences Limited (GLS) completed allottment of shares as part of its Initial Public Offering (IPO) and Offer for Sale (OFS). The company offered 6.3 million equity shares of Rs 2 each through OFS and resulted in a gain of Rs 4,303.33 (net of related expenses and cost of equity shares) and recorded as an exceptional item in the standalone financial results. Pursuant to requirements of Ind AS 110 para 23 and B96 such gain and tax thereon is directly recognised in equity in consolidated financial statements. Post the sale and IPO, the Company's holding in equity shares of GLS has reduced from 100% to 82.84 %.

- The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
- As at 30th June, 2022, pursuant to Employee Stock Options Scheme 2016, 78,717 options were outstanding, which upon exercise are convertible into equivalent number of equity shares. The list of subsidiaries as of 30th June, 2022 is provided in Annexure A.
- 9 The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter ended 30th June, 2022.
- 10 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 11 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Annexure A List of entities included in the consolidated financial results for quater ended 30 June 2022

- 1 Glenmark Pharmaceuticals Europe Ltd., U.K. 2 Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. (liquidated with effect from 4 January 2022) 3 Glenmark Pharmaceuticals S.R.O. 4 Glenmark Pharmaceuticals SK, S.R.O. 5 Ichnos Sciences SA 6 Glenmark Holding S.A. 7 Glenmark Pharmaceuticals SP z.o.o. 8 Glenmark Pharmaceuticals Inc. 9 Glenmark Pharmaceutical Pharmaceuticals Colombia SAS, Inc. 22 Glenmark Pharmaceuticals (Nigeria) Ltd 23 Glenmark Pharmaceuticals (Australia) Pty Ltd 25 Glenmark Pharmaceuticals (Outralia) Pty Ltd 27 Glenmark Pharmaceuticals (Nigeria) Ltd 27 Glenmark Pharmaceuticals (Thailand)
- Co. Ltd 28 Glenmark Pharmaceuticals B.V. 29 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Kenya Ltd 32 Viso Farmaceuticals S.L., Spain 33 Glenmark Specialty SA 34 Glenmark Pharmaceuticals Distribution s.r.o. 35 Glenmark Pharmaceuticals Nordic AB 36 Glenmark Ukraine LLC 37 Glenmark Pharmaceuticals Singapore Pte. Ltd. 39 Ichnos Sciences Biotherapeutics SA 40 Ichnos Sciences Inc., USA 41 Glenmark Life Sciences Limited

For and on behalf of the Board of Directors

Glenn Saldanha

epaper.loksatta om







Chairman & Managing Director